Back to Search Start Over

Antibacterial activities and characterization of novel inhibitors of LpxC

Authors :
Andrew S. Waller
Michael George Hunter
Stephen Rupert Chandler
John M. Clements
Ian Johnson
Jac Wijkmans
Fanny Coignard
Shilpa Palan
Source :
Antimicrobial agents and chemotherapy. 46(6)
Publication Year :
2002

Abstract

Lipid A is the hydrophobic anchor of lipopolysaccharide (LPS) and forms the major lipid component of the outer monolayer of the outer membrane of gram-negative bacteria. Lipid A is required for bacterial growth and virulence, and inhibition of its biosynthesis is lethal to bacteria. UDP-3- O -( R -3-hydroxymyristoyl)- N -acetylglucosamine deacetylase (LpxC) is a metalloenzyme that catalyzes the second step in the biosynthesis of lipid A. Inhibitors of LpxC have previously been shown to have antibiotic activities. We have screened a metalloenzyme inhibitor library for antibacterial activities against an Escherichia coli strain with reduced LpxC activity. From this screen, a series of sulfonamide derivatives of the α-( R )-amino hydroxamic acids, exemplified by BB-78484 and BB-78485, have been identified as having potent inhibitory activities against LpxC in an in vitro assay. Leads from this series showed gram-negative selective activities against members of the Enterobacteriaceae , Serratia marcescens , Morganella morganii , Haemophilus influenzae , Moraxella catarrhalis , and Burkholderia cepacia . BB-78484 was bactericidal against E. coli , achieving 3-log killing in 4 h at a concentration 4 times above the MIC, as would be predicted for an inhibitor of lipid A biosynthesis. E. coli mutants with decreased susceptibility to BB-78484 were selected. Analysis of these mutants revealed that resistance arose as a consequence of mutations in the fabZ or lpxC genes. These data confirm the antibacterial target of BB-78484 and BB-78485 and validate LpxC as a target for gram-negative selective antibacterials.

Details

ISSN :
00664804
Volume :
46
Issue :
6
Database :
OpenAIRE
Journal :
Antimicrobial agents and chemotherapy
Accession number :
edsair.doi.dedup.....f9ed5cab3a7904ba6b406d9d367a7c42